Tryp Therapeutics Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.0501
- Today's High:
- $0.0736
- Open Price:
- $0.0525
- 52W Low:
- $0.04
- 52W High:
- $0.15
- Prev. Close:
- $0.0736
- Volume:
- 32700
Company Statistics
- Market Cap.:
- $6.26 million
- Book Value:
- -0.022
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -139.91%
- Return on Equity TTM:
- -1195.86%
Company Profile
Tryp Therapeutics Inc had its IPO on under the ticker symbol TRYPF.
The company operates in the Healthcare sector and Biotechnology industry. Tryp Therapeutics Inc has a staff strength of 0 employees.
Stock update
Shares of Tryp Therapeutics Inc opened at $0.05 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.05 - $0.07, and closed at $0.06.
This is a -25.27% slip from the previous day's closing price.
A total volume of 32,700 shares were traded at the close of the day’s session.
In the last one week, shares of Tryp Therapeutics Inc have slipped by -12%.
Tryp Therapeutics Inc's Key Ratios
Tryp Therapeutics Inc has a market cap of $6.26 million, indicating a price to book ratio of 2.499 and a price to sales ratio of 0.
In the last 12-months Tryp Therapeutics Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $0. The EBITDA ratio measures Tryp Therapeutics Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Tryp Therapeutics Inc’s operating margin was 0% while its return on assets stood at -139.91% with a return of equity of -1195.86%.
In Q1.6666666666667, Tryp Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Tryp Therapeutics Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.04 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Tryp Therapeutics Inc’s profitability.
Tryp Therapeutics Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -0.5199. Its price to sales ratio in the trailing 12-months stood at 0.
Tryp Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.62 million
- Total Liabilities
- $1.84 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Tryp Therapeutics Inc ended 2024 with $1.62 million in total assets and $0 in total liabilities. Its intangible assets were valued at $1.62 million while shareholder equity stood at $-2009113.00.
Tryp Therapeutics Inc ended 2024 with $0 in deferred long-term liabilities, $1.84 million in other current liabilities, in common stock, $-19749148.00 in retained earnings and $0 in goodwill. Its cash balance stood at $1.26 million and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $1.23 million.
Tryp Therapeutics Inc’s total current assets stands at $1.45 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.84 million and inventory worth $0.
In 2024, Tryp Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Tryp Therapeutics Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.06
- 52-Week High
- $0.15
- 52-Week Low
- $0.04
- Analyst Target Price
- $
Tryp Therapeutics Inc stock is currently trading at $0.06 per share. It touched a 52-week high of $0.15 and a 52-week low of $0.15. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.06 and 200-day moving average was $0.06 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 4724.8% of the company’s stock are held by insiders while 4.2% are held by institutions.
Frequently Asked Questions About Tryp Therapeutics Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Tryp Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing psilocybin-related molecules. The company’s Psilocybin-For-Neuropsychiatric Disorders (PFN) program focuses on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain, and other indications. Its program candidate includes TRP-8803, a psilocybin-based drug product for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. The company was formerly known as Artos Pharma Corp. and changed its name to Tryp Therapeutics Inc. in June 2020. Tryp Therapeutics Inc. was incorporated in 2019 and is based in Kelowna, Canada.